Literature DB >> 19729180

Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.

Saeed Shafti-Keramat1, Christina Schellenbacher, Alessandra Handisurya, Neil Christensen, Bärbel Reininger, Sabine Brandt, Reinhard Kirnbauer.   

Abstract

Infection with bovine papillomavirus type 1 (BPV1) or BPV2 induces fibropapillomas in cows and skin sarcoids in horses. Prophylactic vaccination targeting BPV1 and BPV2 may reduce the incidence of these economically important diseases. The L1 major capsid proteins of BPV1 and BPV2 were expressed in Sf-9 insect cells and both self-assembled into virus-like particles (VLPs). Using conformation-dependent monoclonal antibodies (mAb) both type-specific and shared epitopes were detected. Antisera were raised against BPV1 or BPV2 VLP using alum adjuvant, and their (cross)neutralization capacity was tested by C127 neutralization assays using native BPV1 and BPV2 virions, or by BPV1 pseudovirion assay. Antisera induced by either VLP vaccine were able to robustly (cross-)neutralize heterologous as well as homologous types, indicating that BPV1 and BPV2 are closely related serotypes. These results suggest that a monovalent BPV1 (or BPV2) VLP vaccine may potentially protect against both BPV1 and BPV2 infections and associated diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729180      PMCID: PMC3792341          DOI: 10.1016/j.virol.2009.07.036

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  Vaccination against papillomavirus in cattle.

Authors:  M S Campo
Journal:  Clin Dermatol       Date:  1997 Mar-Apr       Impact factor: 3.541

3.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Authors:  Luisa L Villa; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault; Anna R Giuliano; Cosette M Wheeler; Laura A Koutsky; Christian Malm; Matti Lehtinen; Finn Egil Skjeldestad; Sven-Eric Olsson; Margareta Steinwall; Darron R Brown; Robert J Kurman; Brigitte M Ronnett; Mark H Stoler; Alex Ferenczy; Diane M Harper; Gretchen M Tamms; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Frank J Taddeo; Kathrin U Jansen; Mark T Esser; Heather L Sings; Alfred J Saah; Eliav Barr
Journal:  Lancet Oncol       Date:  2005-05       Impact factor: 41.316

4.  Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

Authors:  Diana V Pastrana; Ratish Gambhira; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Timothy D Culp; Neil D Christensen; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

5.  Generation of HPV pseudovirions using transfection and their use in neutralization assays.

Authors:  Christopher B Buck; Diana V Pastrana; Douglas R Lowy; John T Schiller
Journal:  Methods Mol Med       Date:  2005

6.  In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

Authors:  R B Roden; H L Greenstone; R Kirnbauer; F P Booy; J Jessie; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Authors:  Cosette M Wheeler; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Margaret James; Scott Vuocolo; Teresa M Hesley; Eliav Barr
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

8.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Authors:  Darron R Brown; Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Eng Hseon Tay; Patricía Garcia; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Heather L Sings; Margaret James; Teresa M Hesley; Eliav Barr
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

9.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Authors:  Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Cosette M Wheeler; Song-Nan Chow; Dan L Apter; Henry C Kitchener; Xavier Castellsague; Newton S de Carvalho; S Rachel Skinner; Diane M Harper; James A Hedrick; Unnop Jaisamrarn; Genara Am Limson; Marc Dionne; Wim Quint; Bart Spiessens; Pascal Peeters; Frank Struyf; Susan L Wieting; Matti O Lehtinen; Gary Dubin
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

View more
  15 in total

1.  A multimeric L2 vaccine for prevention of animal papillomavirus infections.

Authors:  Subhashini Jagu; Nicole Malandro; Kihyuck Kwak; Hang Yuan; Richard Schlegel; Kenneth E Palmer; Warner K Huh; M Saveria Campo; Richard B S Roden
Journal:  Virology       Date:  2011-09-13       Impact factor: 3.616

2.  In planta production of a candidate vaccine against bovine papillomavirus type 1.

Authors:  Andrew J Love; Sean N Chapman; Slavica Matic; Emanuela Noris; George P Lomonossoff; Michael Taliansky
Journal:  Planta       Date:  2012-06-21       Impact factor: 4.116

3.  Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.

Authors:  E K Hainisch; S Brandt; S Shafti-Keramat; R Van den Hoven; R Kirnbauer
Journal:  Equine Vet J       Date:  2011-09-06       Impact factor: 2.888

4.  Screening for bovine papillomavirus type 13 (BPV13) in a European population of sarcoid-bearing equids.

Authors:  Christoph Jindra; Ann-Kristin Kamjunke; Sarah Jones; Sabine Brandt
Journal:  Equine Vet J       Date:  2021-08-30       Impact factor: 2.692

Review 5.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation.

Authors:  Bettina Hartl; Edmund K Hainisch; Saeed Shafti-Keramat; Reinhard Kirnbauer; Annunziata Corteggio; Giuseppe Borzacchiello; Reinhard Tober; Christina Kainzbauer; Barbara Pratscher; Sabine Brandt
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

7.  Productive infection of bovine papillomavirus type 2 in the placenta of pregnant cows affected with urinary bladder tumors.

Authors:  Sante Roperto; Giuseppe Borzacchiello; Iolanda Esposito; Marita Riccardi; Chiara Urraro; Roberta Lucà; Annunziata Corteggio; Rosarita Tatè; Michele Cermola; Orlando Paciello; Franco Roperto
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

8.  Complete genome sequence of bovine papillomavirus genotype 13 from local yellow cattle in hainan province, china.

Authors:  Feng Pang; Qiaoyun Shi; Li Du; Tianjing Zhao; Ying Cheng; Hanwei Jiao; Jianguo Zhao; Manchuriga Wang; Hui Rong; Hailong Zhou; Fengyang Wang
Journal:  Genome Announc       Date:  2014-12-04

9.  Productive infection of bovine papillomavirus type 2 in the urothelial cells of naturally occurring urinary bladder tumors in cattle and water buffaloes.

Authors:  Sante Roperto; Valeria Russo; Ayhan Ozkul; Annunziata Corteggio; Aylin Sepici-Dincel; Cornel Catoi; Iolanda Esposito; Marita G Riccardi; Chiara Urraro; Roberta Lucà; Dora M Ceccarelli; Michele Longo; Franco Roperto
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Bovine papillomavirus type 2 (BPV-2) E5 oncoprotein binds to the subunit D of the V₁-ATPase proton pump in naturally occurring urothelial tumors of the urinary bladder of cattle.

Authors:  Sante Roperto; Valeria Russo; Giuseppe Borzacchiello; Chiara Urraro; Roberta Lucà; Iolanda Esposito; Marita Georgia Riccardi; Cinzia Raso; Marco Gaspari; Dora Maria Ceccarelli; Rocco Galasso; Franco Roperto
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.